)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Alembic Pharmaceuticals (APLLTD) investor relations material
Alembic Pharmaceuticals Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 25/26 earnings summary4 Nov, 2025
Executive summary
Q2 FY26 revenue grew 16% year-on-year to INR 1,910 crores, with net profit up 20% to INR 185 crores, driven by strong performance across India Branded, US Generics, Ex-US Generics, and API segments.
EBITDA before R&D rose 32% year-on-year to INR 503 crores, with margin improving to 26%; EBITDA margin for Q2 FY26 was 17%.
R&D investment increased 41% year-on-year to 10% of revenue, supporting accelerated product filings and approvals.
Acquisition of Utility Therapeutics completed, marking entry into US branded drugs with PBR for urinary tract infections.
Board approved unaudited financial results for the quarter and half year ended 30 September 2025.
Financial highlights
Half-year revenue up 13% year-on-year to INR 3,621 crores; EBITDA before R&D at INR 927 crores (26% margin), up 28%.
EBITDA post-R&D at INR 613 crores (17% of revenue); net profit margin for Q2 FY26 was 9.67%.
R&D expenses rose 41% year-on-year to INR 187 crores in Q2, mainly for formulation and complex injectables.
Net working capital increased to INR 2,921 crores; net debt rose to INR 1,280 crores due to working capital and acquisition funding.
Interest cost increased to INR 76 crores from INR 71 crores sequentially.
Outlook and guidance
R&D spend for FY26 guided at INR 600-650 crores, expected to remain at 8% of revenue in coming years.
Net debt (excluding PBR launch) expected to gradually reduce in FY27 as new products and facilities ramp up.
EBITDA margin expected to improve to 18-19% in next two years, targeting 20% as capacity utilization rises.
Pipeline includes 10+ product launches in US Generics for H2 FY26.
PBR launch in US expected late Q4 FY26, with initial margin impact but medium- to long-term growth potential.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Alembic Pharmaceuticals earnings date
Q3 25/262 Feb, 2026
Next Alembic Pharmaceuticals earnings date
Q3 25/262 Feb, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Alembic Pharmaceuticals Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic and specialty medicines. The company produces active pharmaceutical ingredients (APIs) and formulations across various therapeutic areas, including cardiology, dermatology, neurology, and anti-infectives. The company is headquartered in Vadodara, India, and its shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage